PERSPECTIVE article
Front. Aging
Sec. Musculoskeletal Aging
Volume 6 - 2025 | doi: 10.3389/fragi.2025.1640030
This article is part of the Research TopicEmerging Challenges and Opportunities in Weight Loss and Obesity Management for Older AdultsView all articles
Moving Beyond the Scale: Musculoskeletal Risks, Evidence Gaps and Emerging Combination Strategies to Optimize the Quality of Weight Loss Pharmacotherapy in Older Adults
Provisionally accepted
Kieran F Reid*
Shalender Bhasin- Brigham and Women's Hospital, Harvard Medical School, Boston, United States
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
The increasing prevalence of obesity among older adults is a significant clinical and public health challenge. In this population, obesity contributes to numerous chronic diseases, functional decline and elevated mortality. This growing concern highlights the urgent need for more effective weight management strategies for older adults. Pharmacologic treatments, particularly GLP-1 receptor agonists and dual agonists, have emerged as promising treatments for weight loss, but their effects remain understudied in older adults. In this article, we discuss the potential musculoskeletal implications associated with the use of weight loss pharmacotherapy among older adults. We emphasize the consequences of lean mass loss, particularly the loss of skeletal muscle mass, which represents a critical determinant of ambulation, physical function and major regulator of metabolic health in older adults. We also describe the adverse risks of weight regain and weight cycling, and the significance of lean mass preservation during weight loss for older individuals. Finally, we identify knowledge gaps associated with safe and effective obesity pharmacotherapy in older adults and emphasize the potential benefits of combining GLP-1 therapies with promyogenic agents, structured exercise, and targeted nutritional interventions for optimizing weight loss quality in this population. These integrated approaches merit further investigation in clinical trials to determine their synergist effects for enhancing body composition while promoting independence, vitality and well-being in older adults undergoing pharmacologic weight loss.
Keywords: Obesity pharmacotherapy, older adults, Musculoskeletal health, lean mass preservation, promyogenic therapy, exercise interventions, multimodality interventions
Received: 03 Jun 2025; Accepted: 08 Oct 2025.
Copyright: © 2025 Reid and Bhasin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Kieran F Reid, kfreid@bwh.harvard.edu
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.